focus -WSS

focus

author：leisure time 2025-09-30 05:07:34 - browse：47252

Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT — The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

“If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico.

The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： How to increase colonoscopy rates? Looks like an AI can help

hotspot

WSS

Update the Apgar Score to remove skin color

ASCO: AstraZeneca says CAR

Pumping milk in bathrooms at health conferences is common

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

FDA endorses new sterilization method for medical devices

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

explore

focus

knowledge

Continuity nursing helped my family in our darkest PICU moments

The Pandemic Treaty must support building strong health systems

New air purifier tech could be key to improving indoor air quality

Pumping milk in bathrooms at health conferences is common

Medical records are filled with copy

With trial win, GSK could get blood cancer drug back on market

Affirmative action in medical school literally saved lives

Inaction leaves children at risk from dangerous chemotherapy drug

In Memoriam: Notable people who died in 2023

Intellia reports positive results for its CRISPR

knowledge

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

The Pandemic Treaty must support building strong health systems

Ionis drug prevents swelling attacks due to hereditary angioedema

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Prior authorization reform is both possible and imperative

hotspot

leisure time

hotspot

hotspot